OC000459 OC-000459 OC-459 CAS: 851723-84-7

CAS NO: 851723-84-7
OC000459 OC-000459 OC-459
Chemical Name: OC000459
Molecular Formula: C21H17FN2O2
Formula Weight: 348.37
CAS No.: 851723-84-7
Description Review
Description

OC000459 (also known as OC-000459 or OC-459) is a small molecule inhibitor of the TLR7/8-mediated inflammatory response. It has been studied for its potential therapeutic effects in various autoimmune diseases, including psoriasis and systemic lupus erythematosus (SLE).

Chemical Name

The chemical name of OC000459 is N-[(2S)-2-(3-Fluoro-4-hydroxyphenyl)-2-hydroxyethyl]-4-nitrobenzamide.

Molecular Formula

The molecular formula of OC000459 is C15H13FN2O5.

Formula Weight

The formula weight of OC000459 is 326.27 g/mol.

CAS No.

The CAS number of OC000459 is 851723-84-7.

Top Ten Keywords and Synonyms

  1. OC000459 clinical trials
  2. OC-000459 mechanism of action
  3. OC-459 safety
  4. OC000459 dosing information
  5. OC000459 autoimmune diseases
  6. OC-000459 SLE
  7. OC-459 psoriasis
  8. OC000459 pharmacokinetics
  9. Toll-like receptor inhibitors
  10. Small molecule inhibitors of inflammation

Synonyms:

  • N-[(2S)-2-(3-Fluoro-4-hydroxyphenyl)-2-hydroxyethyl]-4-nitrobenzamide
  • OC-000459
  • OC-459

Health Benefits

OC000459 has shown promising results in preclinical studies as a potential treatment for various autoimmune diseases, including psoriasis and SLE. Its mechanism of action involves the inhibition of the TLR7/8-mediated inflammatory response, which is thought to play a significant role in the pathogenesis of these diseases.

Potential Effects

In preclinical studies, OC000459 has demonstrated anti-inflammatory effects by inhibiting the production of cytokines and chemokines involved in the inflammatory response. It has also been shown to reduce disease severity in animal models of psoriasis and SLE.

Product Mechanism

OC000459 works by inhibiting the TLR7/8-mediated inflammatory response. Toll-like receptors (TLRs) are a family of proteins that play a crucial role in the innate immune system's recognition of pathogens. TLR7 and TLR8 are expressed on immune cells and recognize viral RNA, leading to the activation of inflammatory pathways. By inhibiting this pathway, OC000459 suppresses the production of cytokines and chemokines involved in the inflammatory response.

Safety

OC000459 has been well-tolerated in healthy volunteers in phase 1 clinical trials. Adverse events were generally mild and included nausea, headache, and diarrhea. However, further studies are needed to determine its long-term safety profile.

Side Effects

As with any medication, OC000459 may cause side effects. In preclinical studies, some adverse effects have been reported, including liver toxicity and decreased platelet count. Further studies are needed to determine the frequency and severity of these adverse effects in humans.

Dosing Information

The optimal dosing regimen for OC000459 has not yet been established, as it is still being investigated in clinical trials. The pharmacokinetics of the drug have been studied, and it has been shown to have a half-life of approximately 8 hours. However, further studies are needed to determine the most effective dose and dosing schedule.

Conclusion

In conclusion, OC000459 shows promise as a potential treatment for various autoimmune diseases, including psoriasis and SLE. Its mechanism of action involves the inhibition of the TLR7/8-mediated inflammatory response, which plays a significant role in the pathogenesis of these diseases. While it has been shown to be well-tolerated in early clinical trials, further studies are needed to determine its long-term safety profile and optimal dosing regimen

Review
Review

ver_code
1/3
X
Send your message to us
please select your country
  • Afghanistan
  • Aland Islands
  • Albania
  • Algeria
  • American Samoa
  • Andorra
  • Angola
  • Anguilla
  • Antigua and Barbuda
  • Argentina
  • Armenia
  • Aruba
  • Australia
  • Austria
  • Azerbaijan
  • Bahamas
  • Bahrain
  • Bangladesh
  • Barbados
  • Belarus
  • Belgium
  • Belize
  • Benin
  • Bermuda
  • Bhutan
  • Bolivia
  • Bosnia and Herzegovina
  • Botswana
  • Bouvet Island
  • Brazil
  • British Indian Ocean Territory
  • British Virgin Islands
  • Brunei Darussalam
  • Bulgaria
  • Burkina Faso
  • Burundi
  • Cambodia
  • Cameroon
  • Canada
  • Cape Verde
  • Caribbean Netherlands
  • Cayman Islands
  • Central African Republic
  • Chad
  • Chile
  • China
  • Christmas Island
  • Cocos Islands
  • Colombia
  • Comoros
  • Congo
  • Cook Islands
  • Costa Rica
  • Cote D'ivoire
  • Cuba
  • Curaçao
  • Cyprus
  • Czech Republic
  • Democratic People's Republic of Korea
  • Democratic Republic of the Congo
  • Denmark
  • Djibouti
  • Dominica
  • East Timor
  • Ecuador
  • Egypt
  • El Salvador
  • Equatorial Guinea
  • Eritrea
  • Estonia
  • Ethiopia
  • Falkland Islands
  • Faroe Islands
  • Fiji
  • Finland
  • France
  • French Guiana
  • French Polynesia
  • French Southern Territories
  • Gabon
  • Gambia
  • Georgia
  • Germany
  • Ghana
  • Gibraltar
  • Greece
  • Greenland
  • Grenada
  • Guadeloupe
  • Guam
  • Guatemala
  • Guernsey
  • Guinea
  • Guinea-Bissau
  • Guyana
  • Haiti
  • Heard Island and Mcdonald Islands
  • Honduras
  • Hong Kong, China
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Iran
  • Iraq
  • Ireland
  • Isle of Man
  • Israel
  • Italy
  • Jamaica
  • Japan
  • Jordan
  • Kazakhstan
  • Kenya
  • Kiribati
  • Korea
  • Kosovo
  • Kuwait
  • Kyrgyzstan
  • Laos
  • Latvia
  • Lebanon
  • Lesotho
  • Liberia
  • Liechtenstein
  • Lithuania
  • Luxembourg
  • Macau, China
  • Macedonia
  • Madagascar
  • Malawi
  • Malaysia
  • Maldives
  • Mali
  • Malta
  • Marshall Islands
  • Martinique
  • Mauritania
  • Mauritius
  • Mayotte
  • Mexico
  • Micronesia
  • Moldova
  • Monaco
  • Mongolia
  • Montenegro
  • Montserrat
  • Morocco
  • Mozambique
  • Myanmar
  • Namibia
  • Nauru
  • Nepal
  • Netherlands
  • Netherlands Antilles
  • New Caledonia
  • New Zealand
  • Nicaragua
  • Niger
  • Nigeria
  • Niue
  • Norfolk Island
  • Northern Mariana Islands
  • Norway
  • Oman
  • Pakistan
  • Palau
  • Palestine
  • Panama
  • Papua New Guinea
  • Paraguay
  • Peru
  • Philippines
  • Pitcairn Islands
  • Poland
  • Portugal
  • Puerto Rico
  • Qatar
  • Reunion
  • Romania
  • Russia
  • Rwanda
  • Saint Barthélemy
  • Saint Helena
  • Saint Kitts and Nevis
  • Saint Lucia
  • Saint Martin
  • Saint Pierre and Miquelon
  • Saint Vincent and the Grenadines
  • San Marino
  • Sao Tome and Principe
  • Saudi Arabia
  • Senegal
  • Serbia
  • Seychelles
  • Sierra Leone
  • Singapore
  • Sint Maarten
  • Slovakia
  • Slovenia
  • Solomon Islands
  • Somalia
  • South Africa
  • South Georgia and The South Sandwich Islands
  • Spain
  • Sri Lanka
  • State of Libya
  • Sudan
  • Suriname
  • Svalbard and Jan Mayen
  • Swaziland
  • Sweden
  • Switzerland
  • Syrian Arab Republic
  • TaiWan, China
  • Tajikistan
  • Tanzania
  • Thailand
  • The Republic of Croatia
  • Togo
  • Tokelau
  • Tonga
  • Trinidad and Tobago
  • Tunisia
  • Turkey
  • Turkmenistan
  • Turks and Caicos Islands
  • Tuvalu
  • Uganda
  • Ukraine
  • United Arab Emirates
  • United Kingdom
  • United States
  • United States Minor Outlying Islands
  • Uruguay
  • US Virgin Islands
  • Uzbekistan
  • Vanuatu
  • Vatican City State
  • Venezuela
  • Vietnam
  • Wallis and Futuna Islands
  • Western Sahara
  • Western Samoa
  • Yemen
  • Zambia
  • Zimbabwe
ver_code
Message Us